This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, F. Articles by Shi, X. Search for Related Content PubMed PubMed Citation Articles by Chen, F. Articles by Shi, X.

(American Journal of Pathology. 2001;159:387-397.)
© 2001 American Society for Investigative Pathology

Review

New Insights into the Role of Nuclear Factor-B in Cell Growth Regulation

From the Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia

	Abstract

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 
The nuclear factor (NF)-B family of eukaryotic transcription factors plays an important role in the regulation of immune response, embryo and cell lineage development, cell apoptosis, cell-cycle progression, inflammation, and oncogenesis. A wide range of stimuli, including cytokines, mitogens, environmental particles, toxic metals, and viral or bacterial products, activate NF-B, mostly through IB kinase (IKK)-dependent phosphorylation and subsequent degradation of its inhibitor, the IB family of proteins. Activated NF-B translocates into the nucleus where it modulates the expression of a variety of genes, including those encoding cytokines, growth factors, acute phase response proteins, cell adhesion molecules, other transcription factors, and several cell apoptosis regulators. During the past few years, tremendous progress has been achieved in our understanding on how intracellular signaling pathways are transmitted in either a linear or a network manner leading to the activation of NF-B and subsequent cell growth control. However, a detailed molecular mechanism of NF-B regulating cell growth has yet to be determined. Elucidation of the relationships between NF-B activation and cell growth will be important in developing new strategies for the treatment of various human diseases, such as chronic autoimmune disorder and cancer.

	Introduction

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

A wide range of signals, which typically include cytokines, mitogens, environmental and occupational particles, toxic metals, intracellular stresses, viral or bacterial products, and UV light, induce expression of early response genes through the NF-B family of transcription factors.^2,4,8-10 In resting cells, NF-B is sequestered in the cytoplasm in an inactive form through its association with one of several inhibitory molecules, including IB-, IB-ß, IB-, p105, and p100. Activation of the NF-B-signaling cascade results in a complete degradation of IB or partial degradation of the carboxyl termini of p105 and p100 precursors, allowing the translocation of NF-B to the nucleus, where it induces transcription (Figure 1) . Activated NF-B binds to specific DNA sequences in target genes, designated as B-elements, and regulates transcription of genes mediating inflammation, carcinogenesis, and pro- or anti-apoptotic reactions.

View larger version (36K): [in this window] [in a new window]   Figure 1. Signaling pathways of NF-B activation. Extracellular inducers, including cytokines, reactive oxygen species (ROS), and viral and bacterial products, activate IKK through upstream kinases directly or indirectly. Activated IKK phosphorylates N-terminal S32 and S36 residues of IB- that is associated with NF-B p50 and p65 heterodimer. The SCF-ß-TrCP complex recognizes phosphorylated IB- and modifies IB- with polyubiquitin chains. This is followed by proteasome-mediated degradation of IB-. After degradation of IB-, the activated NF-B translocates into the nucleus where it binds to the B-sites of gene promoters or enhancers to up-regulate target gene expression. Line arrows and filled arrows denote the NF-B signaling pathways; open arrows denote the connections with the by-standing signaling pathways.

Although the signaling pathways leading to the activation of NF-B have been well defined, a number of questions remain to be answered. For example, it is unclear exactly how many protein subunits comprise a naïve and activated IKK complex, respectively; how the various signaling pathways converge on this kinase complex; what upstream kinases contribute to the phosphorylation and activation of IKK. It is also unclear whether other substrates, in addition to IB or NF-B family members, can be phosphorylated by IKK. Regarding the functional aspects of NF-B transcription factor, we know that although NF-B is important and involved in the regulation of cell apoptosis, cell-cycle transition, and carcinogenic transformation,²⁰ the detailed interconnections among NF-B activation, cell cycle, and apoptosis are still undefined. Considering the fact that aberrant activation of NF-B is associated with a wide range of human diseases, elucidation of molecular mechanisms determining NF-B activation and expression of its various functions may lead to the development of novel preventive and therapeutic strategies for many diseases including chronic inflammation and cancer.

	Roles of NF-B Activation in Cell Apoptosis

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 
Programmed cell death, or apoptosis, is an essential mechanism for any multicellular organism to eliminate cells that are in excess or potentially dangerous.²¹ Most apoptotic cells are characterized by unique morphological features, such as membrane blebbing, cell shrinking, cytosolic and nuclear condensation, and breakdown of chromosomal DNA. Depending on the use of different initiating caspases, signal-induced apoptosis can be roughly divided into receptor-mediated extrinsic apoptosis and mitochondrial-mediated intrinsic apoptosis (Figure 2) .^22,23 The extrinsic apoptotic pathway is triggered as a consequence of ligand binding to death receptors, including tumor necrosis factor (TNF)-R, Fas, OX40, CD40, and 4–1BB, which contain conserved protein-protein-binding domains termed death domains. These receptors recruit procaspases, mainly caspase-8, via adapter molecules. The intrinsic apoptotic pathway is mediated by mitochondria through release of apoptosis-promoting factors, including cytochrome c, apoptosis-inducing factor, and Diablo/Smac.^24-27 Cytochrome c forms a complex with a cytosolic protein named Apaf-1, a flavoprotein with homology to plant ascorbate reductases and bacterial NADH oxidases, to activate caspase-9.²⁷ Whereas apoptosis-inducing factor released from the intermembranous space of damaged mitochondria induces apoptosis in a caspase-independent manner, Smac/Diablo released from mitochondria promotes apoptosis by binding to and antagonizing XIAP, cIAP1, and cIAP2, allowing the activation of caspases.^25,26 Both activated caspase-8 from the extrinsic apoptotic pathway and activated caspase-9 from the intrinsic apoptotic pathway cleave and activate effector caspases, mainly caspase-3 to execute an apoptotic process. These apoptotic pathways, however, were compromised in many cases because of the activation of caspase-independent signaling cascades that function to block the apoptotic responses. A good example is TNF-R-mediated activation of NF-B that induces expression of anti-apoptotic proteins, including caspase inhibitors, such as cIAP1, cIAP2, and XIAP, and mitochondria membrane stabilizers, such as Bcl-xl and Bfl-1.^28-30

View larger version (19K): [in this window] [in a new window]   Figure 2. Possible targeting point of anti-apoptotic signals from NF-B. Intrinsic (open arrows) and extrinsic (filled arrows) apoptosis pathways are depicted. The effector caspases, such as caspase-3 and caspase-7, are activated by upstream initiator caspases, caspase-8 and caspase-9. The initiator caspases themselves are activated by either ligands binding to the death receptor complex or cytochrome c released from damaged mitochondria. An anti-apoptotic effect of NF-B is achieved through its up-regulation of IAPs that inhibits caspases and Bcl-xl that protects mitochondria from further damaging., activation; , inhibition.

With the identification of role of NF-B in transcriptional regulation of several pro-apoptotic genes, such as fas and fasl, controversy raged as reports demonstrating that NF-B protected cells from apoptosis in some types of cells were matched by a similar number of reports demonstrating that it did not in other types of cells.^35,36 Based primarily on earlier studies, NF-B was initially considered a pro-apoptotic factor because of its rapid activation in cells in response to apoptotic signals and its involvement in the expression of some apoptotic genes, including TNF-, c-myc, and fasl.^37,38 More recent work, however, has altered this view and revealed an anti-apoptotic effect of NF-B in response to a variety of apoptotic stimuli.

The direct evidence for the anti-apoptotic effects of NF-B is provided by gene knockout studies in which the genes encoding either members of NF-B family proteins or upstream kinases were disrupted. RelA (p65)-deficient mice die during embryonic development through apoptosis of hepatocytes.³⁹ IKK-ß gene knockout mice and IKK-ß/IKK- double-knockout mice die as embryos and show massive liver cell apoptosis,^40-42 a phenotype similar to the response of NF-B p65 gene knockout mice. In addition, knockout of the IKK- gene results in perinatal lethality of mice with an increased thickness of the skin because of the deficiency of keratinocyte differentiation.⁴³ Male mice with an inactivated X-linked gene encoding IKK-/NEMO, an essential modulator of the IKK complex for NF-B activation, die at mid-gestation because of a massive apoptosis of cortical and medulla lymphocytes in the thymus, in addition to degeneration of the liver.^44,45 Female mice deficient in the IKK-/NEMO gene manifest a unique dermatopathy because of the apoptosis of keratinocytes and consequent abnormal pigmentation, a characteristic strikingly similar to that of the human X-linked dominant, male-lethal genetic disease—incontinential pigmenti or Bloch-Sulzberger Syndrome. Cross-breeding of relA or IKK-ß gene knockout mice with TNF-R1 or TNF- gene knockout mice revealed partial rescue of embryonic lethality, suggesting that NF-B deficiency sensitized cells in response to TNF--mediated cytotoxicity.^46,47 Similarly, mice deficient in both TNF-R1 and IKK-ß showed an attenuated embryonic liver apoptosis.⁴⁸

Other compelling evidence linking NF-B with an anti-apoptotic effect is based on the studies indicating that NF-B is a priming factor for liver regeneration after partial hepatectomy.⁴⁹ This priming effect of NF-B might be through its transcriptional regulation for survival genes or anti-apoptotic genes whose products can block stress signal-induced cell death, a process critically involved in cell proliferation and transformation. Candidate anti-apoptotic genes targeted by NF-B include those encoding the cell-cycle regulatory protein cyclin D1,^50-52 the mitochondrial membrane-stabilizing proteins Blf-1 and Bcl-xl,^53,54 the caspase inhibitors cIAP1/cIAP2 and XIAP, and the TNF receptor-associated factors TRAF1 and TRAF2.⁵⁵ It should be noted that several reports suggest that NF-B is also a pro-apoptotic factor in FasL-induced cell death.^56,57 This argument is primarily based on earlier observations that NF-B can regulate the artificial promoter activity of the fasl gene, a gene encoding an important activator of apoptosis through a CD95/Fas- and Fas-associated death domain (FADD)-mediated caspase-8 activation pathway.²² However, both promoter truncation studies of the fasl gene and somatic cell mutagenesis studies of IKK- indicate that NF-B is not required for the fasl gene expression.^58,59 Nevertheless, pro-apoptotic or anti-apoptotic effects of NF-B might depend on the cellular context in combination with a bewildering variety of activators.

Further support for the anti-apoptotic effect of NF-B comes from observations in which NF-B can protect cortical neurons from ß-amyloid peptide-induced apoptosis in Alzheimer’s disease.^60,61 Exposure of cortical neurons to ß-amyloid peptide increased levels of IB- mRNA and protein and a consequent decrease in NF-B activity.⁶⁰ Elevation of NF-B activity by pretreatment of these cells with an antisense oligonucleotide to IB- protected them from ß-amyloid peptide-induced apoptosis. Conversely, blockade of NF-B activity by B decoy DNA was associated with enhanced ß-amyloid peptide-induced mitochondrial dysfunction and cell apoptosis.⁶¹ Moreover, data from the studies of rodent models of stroke or cardiac arrest suggested that NF-B might possibly prevent ischemic neuronal degeneration.⁶² The protective role of NF-B on neurons was attributed to NF-B-mediated transcription of genes encoding Bcl-2, Mn-SOD, and proteins regulating cellular calcium homeostasis.⁶³

The vast majority of studies focused on the regulatory roles of NF-B on apoptosis suggest that NF-B is acting on the upstream pathways of apoptosis, either negatively or positively. Conversely, a few recent studies have demonstrated the possible regulation of apoptotic molecules on NF-B. Of potential interest regarding regulation of NF-B by apoptotic molecules are the observations of cross-competition between NF-B and p53, a major pro-apoptotic protein.^64-69 The molecular events identified thus far as mediators of cross-competition between NF-B and p53 can be roughly classified into two categories: the upstream kinases or other regulatory molecules that relay input signals into NF-B and p53, and co-factors that affect transcriptional activities of NF-B and p53. An earlier study conducted by Jung and colleagues⁷⁰ indicated that ATM, a major kinase responsible for DNA damage-induced N-terminal phosphorylation of p53, was involved in IB- phosphorylation in SV40 large T-transformed fibroblasts in response to ionizing radiation. In nontransformed fibroblasts, however, Ashburner and colleagues⁷¹ demonstrated a lack of involvement of ATM in IB- phosphorylation. In an in vitro study, Liu and colleagues⁷² reported that DNA-dependent protein kinase (DNA-PK), a kinase phosphorylating p53 in response to DNA damage, was able to phosphorylate the carboxyl terminus of IB- protein. On the functional level, the first evidence of mutual functional regulation between NF-B and p53 was from the observation that p53 could antagonize NF-B activity by cross-competition for a limiting pool of the co-activator, p300.⁶⁵ In contrast, two recent studies indicated that p53 might activate NF-B through an unknown mechanism⁷³ or stimulate the activity of NF-B through induction of its target gene, p21^Waf1, which inhibits cyclin E/Cdk2 activity and blocks its ability to compete with NF-B for co-factors, such as p300 and CBP.⁷⁴

Further evidence indicating that apoptotic molecules regulate NF-B comes from study of caspase cleavage of NF-B p65 subunit or IB- protein.^75-77 The cleavage of p65 by caspase-3 leads to a loss of the carboxyl-terminal transactivation domain.⁷⁵ The carboxyl terminal truncated p65 is transcriptionally inactive. The cleavage of IB- by caspase-3 has been observed in -radiation-induced apoptosis and NF-B inhibition-induced apoptosis.^77,78 A caspase-3 cleavage site has been identified in the region of amino acids 26 to 32 of human IB- and 32 to 37 of chicken IB- protein.⁷⁶ The cleavage site of caspase-3 on IB- with the amino acid sequence D-R-H-D-S resembles the consensus caspase-3 cleavage site, D-X-X-D-G/S/A, where X represents any amino acid residue. Cleavage of IB- by caspase-3 creates a N-terminal truncated IB- protein that is resistant to degradation by proteasome in response to inducers of NF-B, but is able to bind to and suppress NF-B. Therefore, the role of caspase-3 cleavage on IB- and p65 is to ensure that the anti-apoptotic gene is suppressed and apoptotic process is not interrupted once the cells are committed to apoptotic elimination.

In contrast, several studies indicate that caspases might also participate in the activation of NF-B under certain circumstances. One example supporting this notion is the involvement of Dredd, a caspase encoded by Drosophila dredd gene, in the endoprotease cleavage of the Relish protein.⁷⁹ Structurally similar to human p100 and p105, two precursor proteins of NF-B family, Relish contains a N-terminal Rel homology domain and a C-terminal IB-like region. On lipopolysaccharide stimulation, Relish undergoes a rapid cleavage between the Rel homology domain and IB-like region. Proteasome inhibitors failed to prevent the cleavage of Relish. In contrast, introducing a dominant-negative mutant of Dredd to inhibit the caspase activity of Dredd significantly blocked the cleavage of Relish, indicating caspase, rather than proteasome, is required for the activation of NF-B-like protein in Drosophila. In addition, in mammalian cells, caspase-8, caspase-10, and MRIT, three death effector domain-containing proteins, have been shown to be able to activate upstream signals, such as NIK and IKK, leading to the activation of NF-B.⁸⁰ This activity seems to be mainly dependent on the interaction between the prodomain of caspases and IKK. Furthermore, several recent studies suggested that other apoptosis-inducing proteins, such as Nod2, an Apaf-1 family member, and BclI0 and vCLAP, two caspase-recruitment domain-containing proteins, could also activate NF-B through the interaction with IKK- subunit of IKK complex.^81-83 However, it is hard to reconcile these observations with the notions that NF-B is repressed in the cells undergoing apoptosis.^33,77,78

	NF-B and Cell-Cycle Regulation

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 
It has been known for decades that multiple signals are required to maintain proper cell growth and tissue homeostasis.⁸⁴ Most cells within a normal tissue may be forced out of the active cell cycling into a quiescent (G₀) state from which they may re-enter cell cycling under some future circumstances. In a mature tissue, cells may be induced to terminal differentiation by relinquishing their proliferative or cell-cycling potential. Control of the orderly progression of dividing cells through the G₁, S, G₂, and M phases of the cell cycle in eukaryotic cells relies on a series of cell-cycle regulatory proteins, mainly cyclins that exert their function by binding to and activating a number of specific cyclin-dependent kinases (CDKs). The CDK activity is further modulated by kinases and phosphatases that phosphorylate and dephosphorylate CDK, respectively. Moreover, CDKs are subject to regulation by association with one of a number of specific CDK inhibitors or cell-cycle checkpoint proteins, such as p21^Waf1, p16^INK4a, p27^Kip1,⁸⁵ and growth arrest and DNA-damage protein 45 (GADD45) (Figure 3) .⁸⁶

View larger version (29K): [in this window] [in a new window]   Figure 3. Involvement of NF-B in cell-cycle regulation. NF-B may facilitate cell-cycle transition from G1 to S phase by antagonizing the activation or function of p53 and up-regulating cyclin D1 gene expression. NF-B may also promote G2- to M-phase transition by down-regulating the expression of GADD45, a G2/M phase blocker that inhibits CDC2/cyclin B complex., activation; , inhibition.

The relationship between NF-B and apoptosis has been intensively explored during the last few years, whereas only limited information is available regarding the possible involvement of NF-B in cell-cycle regulation in cellular response to a variety of stress signals. A critical role for NF-B in cell-cycle progression was suggested by earlier observations that NF-B activity was elevated during the G₀ to G₁ cell-cycle transition in mouse fibroblasts.⁹¹ A series of recent studies has begun to elucidate that in addition to fibroblasts, NF-B activation was required for cell cycling in other types of cells, such as regenerating liver cells and estrogen receptor-negative breast cancer cells.^91-95 It was also found that the levels of NF-B activation were linked to signaling that controls cell-cycle progression in HeLa cells and Jurkat T cells.^74,96 Inhibition of NF-B caused impairment of cell-cycle progression in human glioma cells⁹⁷ and a retarded G₁/S transition in HeLa cells.⁹⁸ The identification of NF-B binding sites in the promoter region of cyclin D1 gene provided direct evidence for the contributions of NF-B to the cell cycle.^50-52,95 Cyclin D1, in association with cyclin-dependent kinases, CDK4 and CDK6, promotes G₁/S phase transition through CDK-dependent phosphorylation of pRb, thereby releasing the transcription factor E2F, which is required for the activation of S phase-specific genes.^99-101 Two NF-B binding sites in the human cyclin D1 promoter have been identified. Inhibition of NF-B by a degradation-resistant IB- caused a pronounced reduction of serum-induced cyclin D1 expression accompanied by a decrease of cyclin D1-associated kinase activity and delayed phosphorylation of pRb.

In contrast, several recent reports also indicated that NF-B activation is necessary to cause cell-cycle arrest and/or induce cells to commit to terminal differentiation. Overexpression of NF-B p65 or c-Rel arrests G₁/S cell-cycle transition in pro-B cells and HeLa cells, respectively.^96,102 In HeLa cells, overexpression of c-Rel arrests cells at the G₁/S phase because of the stabilization of p53 protein, which can subsequently activate the expression of p21^Waf1, a potent inhibitor of CDK2.⁹⁶ The elevated levels of p21^Waf1 correlated with the accumulation of the hypophosphorylated form of pRb and a decrease in E2F DNA binding. It is unclear how overexpression of c-Rel resulted in a prolonged half-life of p53 protein. In pro-B cells, although overexpression of c-Rel exhibited no effect on cell-cycle regulation, overexpression of p65 caused G₁ arrest and subsequent apoptosis. This G₁-arresting effect of p65, however, seems to be dependent on cell developmental stage, because overexpression of p65 did not cause G₁ arrest in mature B cells. It remains unsettled whether manipulation of NF-B signaling using protein overexpression can lead to consequences that are physiologically relevant. If it is, one may speculate that inhibition of NF-B should cause over-cycling or hyperproliferation. Indeed, data obtained by gene inactivation of IKK- in the mouse indicated an unexpected excessive proliferation of the skin basal layer because of the absence of epidermal differentiation.^103,104 NF-B activity could not be found in keratinocytes from IKK--null mouse skin. These results point to a unique role for NF-B in the epidermis, that is, NF-B forces keratinocytes out of cell cycle and subsequent terminal differentiation. In this regard, the response of the epidermal keratinocytes to NF-B seem to be opposite from that of other cell types, such as lymphocytes and macrophages, where NF-B seems to promote cell-cycle transition.^50-52,95

Although most of the studies so far addressed the effects of NF-B on G₁/S phase regulation, the question of whether NF-B also contributes to G₂/M phase transition has not been explored. In a recent study in human bronchial epithelial cell line, BEAS-2B, we found that NF-B inhibition by stable expression of a kinase mutated form of IKK-ß potentiated toxic metal-induced G₂/M cell-cycle arrest.¹⁰⁵ First, flow cytometric analysis demonstrated that at 48 hours after arsenite treatment, BEAS-2B cells expressing a kinase-mutated form of IKK-ß showed a marked dose-dependent increase of cells arrested in the G₂/M phase and a corresponding decrease in the number of cells in G₁ phase. Second, a dose-dependent induction of GADD45 protein was observed in cells treated with arsenite. This induction of GADD45 by arsenite seems to be dependent on the activation of c-Jun-N-terminal kinase, because blockage of c-Jun-N-terminal kinase activation by expression of a dominant-negative SEK1 vector decreased the induction of GADD45. On the other hand, inhibition of NF-B by expressing a kinase-mutated form of IKK-ß increased GADD45 induction by arsenite. Third, analysis for the expression of CDC25 family members revealed that arsenite induced de novo CDC25A expression, but markedly reduced the levels of CDC25B and CDC25C proteins, two phosphatases dephosphorylating and activating CDC2/cyclin B complex required for the transition of the cell cycle from G₂ to M phase. The effects of Cr(VI) on the regulation of the cell cycle were also determined and revealed to be more complicated. Although Cr(VI) was able to induce GADD45 and suppress both CDC25B and CDC25C, it had no effect on CDC25A. Cell-cycle-profiling studies showed that whereas a lower concentration of Cr(VI) (0.25 µg/ml) promoted cell-cycle transition, higher concentrations of Cr(VI) (1 to 4 µg/ml) arrested cells at S phase. In the case of vanadate-induced cell-cycle regulation, the cell-cycle-arresting effect of vanadate seems to be dependent on the status of NF-B activation. In normal epithelial cells, vanadate exhibited less effect on cell-cycle transition. However, in the cells where NF-B activation was specifically inhibited, vanadate showed a marked G₂/M phase-arresting effect. However, vanadate was unable to induce the expression of GADD45, an inhibitor of cyclin B/CDC2 complex required for G₂/M transition (Chen et al, unpublished observations).

	NF-B and Oncogenesis

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 
The ability of NF-B to suppress apoptosis and to regulate cell-cycle transition clearly indicates that NF-B may participate in many aspects of oncogenesis. Indeed, elevation of NF-B activity is evident in a number of human cancers, including breast cancer,¹⁰⁶ non-small cell lung carcinoma,¹⁰⁷ thyroid cancer,¹⁰⁸ T- or B- lymphocyte leukemia,¹⁰⁹ melanoma,¹¹⁰ colon cancer,¹¹¹ bladder cancer,¹¹² and several virally induced tumors.^113-115 The earliest evidence for a role for NF-B in oncogenic transformation has been derived from the fact that v-Rel, a highly oncogenic retroviral homologue of c-Rel, causes carcinogenesis in avian lymphoid cells.¹⁰⁸ Later studies suggested that v-Rel also has the capacity of transforming mammalian cells in vivo.¹¹⁶ Transgenic mice expressing v-Rel under the control of the T-cell-specific lck promoter develop T-cell lymphomas. Inhibition of NF-B by overexpression of a degradation-resistant IB- delays the development of T-cell lymphomas and prolongs the survival of v-Rel transgenic mice.¹¹⁶

Chromosomal alterations of NF-B family genes provided additional evidence for the role of NF-B in oncogenesis. It has been demonstrated that genes encoding c-Rel, NF-B2 (p100/p52), p65/RelA, and Bcl-3 proteins are all located within breakpoint regions of the genome that are involved in oncogenic rearrangements or amplifications. Rearrangement of nfkb2 gene by t(10,14) chromosomal translocation causes deletions of sequences encoding the ankyrin repeat motif of p100. Consequently, this carboxyl terminal truncated p100 is constitutively located in the nucleus of cells, which has been originally found in a case of B-cell non-Hodgkin’s lymphoma and observed in a number of lymphoid neoplasms, particularly cutaneous lymphomas.^117-119 Rearrangement and amplification of c-Rel gene has also been found in numerous non-Hodgkin’s lymphomas and cancer cell lines.^108,120 The bcl-3 gene, which encodes an IB-like protein that regulates transcriptional activity of NF-B p50 or p52 homodimer, was identified as a [t(14, 19)(q32;q13.1)] chromosomal translocation in many cases of chronic lymphocytic leukemia.¹²¹ Unlike rearrangement of the nfkb2 gene, alterations at the bcl-3 locus do not truncate or change the coding sequence, but rather cause overexpression of bcl-3 mRNA. In malignant Hodgkin and Reed-Sternberg (H/RS) cells from Hodgkin’s lymphoma, mutations in the IB- gene have been detected and are suggested to cause a sustained activation of NF-B.¹²²

Accumulating evidence reveals that tumorigenesis or oncogenesis is a multistep process and that these steps reflect defections in regulatory circuits that govern normal cell proliferation, differentiation, and death.¹²³ Although abnormal activation or function of NF-B has been clearly demonstrated in the initiation or facilitation of oncogenesis, the central question that has to be answered is: how many and what steps are influenced by NF-B. NF-B has been shown to antagonize the function of p53 as discussed earlier.⁶⁵ Obviously, this antagonism of p53 by NF-B will result in the evasion of cells from stress-induced cell-cycle arrest and/or programmed cell death and consequently sensitize the cells for genomic instability. Furthermore, NF-B could promote cell-cycle transition by a direct transcriptional up-regulation of the cyclin D1 gene.^50-52,95 Although it remains to be confirmed, this increased expression of cyclin D1 may possibly provide cells with an uncontrolled or limitless replicative potential. Up-regulation of anti-apoptotic genes, such as cIAP1, cIAP2, XIAP, and bcl-xl, by NF-B,⁴ is an additional mean of cells to escape from or resist signal-induced apoptosis. Other NF-B-regulated genes include those encoding intercellular adhesion molecule-1,⁵ extracellular matrix protein tenascin-C,¹²⁴ vascular endothelial growth factor,¹²⁴ chemokines, and cyclooxygenase-2.¹²⁴ These gene products are directly associated with the tumor cell metastasis and tumor tissue angiogenesis.

The key role that NF-B plays on multiple steps of oncogenesis makes this factor a central and favorable target for therapeutic intervention of cancer, especially, certain types of leukemia or lymphomas.¹²⁵ Indeed, experimental data suggest that inhibition of NF-B by antisense oligonucleotides to relA, degradation resistant IB-, and aspirin or nonsteroidal anti-inflammatory drugs, could enhance the efficacy of cancer chemotherapies and radiation.^126,127 Studies by Wang and co-workers^55,128 showed that inhibition of NF-B by infecting the cells with an adenovirus carrying a modified form of IB- (superrepressor IB-) leads to dramatically enhanced apoptosis of HT1080 fibrosarcoma cells in response to ionizing radiation or daunorubicin treatment. Consistent with these reports, working with pancreatic cancer cell lines exposed to VP16 or doxorubicin, Arlt and colleagues¹²⁹ demonstrated recently that NF-B inhibition by pharmacological proteasome inhibitors or transfection of the cells with a N-terminal-truncated IB- variant efficiently reduces chemoresistance of these cells. Using similar or different approaches to inhibit NF-B, this effect has also been noted in a variety of other cell types including non-small cell lung cancers,¹³⁰ head and neck squamous carcinomas,¹³¹ human myeloblastic leukemia cells,¹³² colorectal cancer,¹³³ and bladder cancer cells.¹¹² Despite these encouraging observations, however, care has to be taken when using different approaches to inhibit NF-B that might be attributable to the process of oncogenesis. Indeed, different approaches for the inhibition of NF-B does not necessarily lead to the same extents of inactivation of NF-B because of the existence of functionally and stoichiometrically different NF-B complexes that respond to different activation signals.⁵ Also, the inhibitory effect of NF-B inhibitors can vary considerably between different cell types because of unique simultaneous or asynchronous events triggered by these inhibitors in any given cell type.¹³⁴

	Summary

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 
The detailed molecular mechanisms by which the NF-B transcription factor contributes to cell growth control, such as cell apoptosis, cell-cycle transition, and oncogenesis remain to be further determined. One of the major challenges in understanding mechanisms of cell growth regulation by NF-B in response to environmental stress is to elucidate how signal transduction pathways are activated and how signaling cross-talk and specificity are achieved when several signaling pathways are activated simultaneously by stress inducers that elicit different cellular responses. For instance, why does activation of the NF-B, an anti-apoptotic transcription factor, coincide with obvious apoptotic features in cells undergoing stress responses? Because many stress inducers and their mediators are highly reactive but nonspecific, an activation of only one specific signaling pathway is hard to achieve in the cells in response to a particular inducer. Even in a single signaling pathway, because of their highly reactive and nonspecific characteristics, certain stress inducers and their mediators can in principle induce conflicting signals by affecting signaling molecules at different levels. A good example is the effects of oxidative stress on NF-B signaling pathway. It has been frequently observed in certain types of cells that oxidative stress amplified or potentiated NF-B activation, whereas at the same time oxidation of IKK or NF-B proteins inhibited NF-B function. Translating the knowledge gained by studying the connections among NF-B activation, cell apoptosis, cell-cycle regulation, and oncogenesis may aid in identifying novel preventive and therapeutic measures for diseases, such as chronic inflammation and cancer.

	Acknowledgements

 
We thank our colleague Dr Murali Rao for helpful suggestions and critique of the manuscript; and to the many friends whose primary valuable work in the related fields we could not directly acknowledge because of space constrains. Dr. Fei Chen thanks the Health Effects Laboratory Division of National Institute for Occupational Safety and Health for support through a cooperative agreement from the Association of Teachers of Preventive Medicine and the Centers for Disease Control and Prevention of the United States.

	Footnotes

 
Address reprint requests to Dr. Fei Chen, PPRB of NIOSH, 1095 Willowdale Rd., Morgantown, WV 26505. E-mail: lfd3{at}cdc.gov

Supported by a Career Development Award in Genetics under a cooperative agreement from the Centers for Disease Control and Prevention through the Association of Teachers of Preventive Medicine (to F. C.).

Accepted for publication April 19, 2001.

	References

Top Abstract Introduction Roles of NF-{kappa}B Activation... NF-{kappa}B and Cell-Cycle... NF-{kappa}B and Oncogenesis Summary References

 

1. Zandi E, Karin M: Bridging the gap: composition, regulation, and physiological function of the IB kinase complex. Mol Cell Biol 1999, 19:4547-4551[Free Full Text]
2. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-B activity. Annu Rev Immunol 2000, 18:621-663[Medline]
3. Israel A: The IKK complex: an integrator of all signals that activate NF-B? Trends Cell Biol 2000, 10:129-133[Medline]
4. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999, 45:7-17[Abstract/Free Full Text]
5. Baldwin AS, Jr: The NF-B and IB proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683[Medline]
6. Ghosh S, May MJ, Kopp EB: NF-B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260[Medline]
7. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-B. Annu Rev Cell Biol 1994, 10:405-455
8. Pahl HL: Activators and target genes of Rel/NF-B transcription factors. Oncogene 1999, 18:6853-6866[Medline]
9. Gilmore TD: The Rel/NF-B signal transduction pathway: introduction. Oncogene 1999, 18:6842-6844[Medline]
10. Sun SC, Ballard DW: Persistent activation of NF-B by the tax transforming protein of HTLV-1: hijacking cellular IB kinases. Oncogene 1999, 18:6948-6958[Medline]
11. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL: Prokaryotic regulation of epithelial responses by inhibition of IB ubiquitination. Science 2000, 289:1560-1563[Abstract/Free Full Text]
12. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-B1 precursor protein and the activation of NF-B. Cell 1994, 78:773-785[Medline]
13. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV: IB kinase-ß: NF-B activation and complex formation with IB kinase- and NIK. Science 1997, 278:866-869[Abstract/Free Full Text]
14. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A: IKK-1 and IKK-2: cytokine-activated IB kinases essential for NF-B activation. Science 1997, 278:860-866[Abstract/Free Full Text]
15. Cohen L, Henzel WJ, Baeuerle PA: IKAP is a scaffold protein of the IB kinase complex. Nature 1998, 395:292-296[Medline]
16. Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA, Scheidereit C: The IB kinase (IKK) complex is tripartite and contains IKK but not IKAP as a regular component. J Biol Chem 2000, 275:29779-29787[Abstract/Free Full Text]
17. Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, Haag M, Stark GR: Act1, an NF-B-activating protein. Proc Natl Acad Sci USA 2000, 97:10489-10493[Abstract/Free Full Text]
18. Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U: CIKS, a connection to IB kinase and stress-activated protein kinase. Proc Natl Acad Sci USA 2000, 97:10494-10499[Abstract/Free Full Text]
19. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, Kaneko Y, Nimura Y, Motoyama N, Ikeda K, Karin M, Nakanishi M: NAK is an IB kinase-activating kinase. Nature 2000, 404:778-782[Medline]
20. Huang S, DeGuzman A, Bucana CD, Fidler IJ: Nuclear factor-B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000, 6:2573-2581[Abstract/Free Full Text]
21. Strasser A, O’Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem 2000, 69:217-245[Medline]
22. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998, 281:1305-1308[Abstract/Free Full Text]
23. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312[Abstract/Free Full Text]
24. De Laurenzi V, Melino G: Apoptosis. The little devil of death. Nature 2000, 406:135-136[Medline]
25. Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42[Medline]
26. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53[Medline]
27. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446[Medline]
28. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259[Medline]
29. Reed JC: Bcl-2 family proteins. Oncogene 1998, 17:3225-3236[Medline]
30. Dahl AM, Klein C, Andres PG, London CA, Lodge MP, Mulligan RC, Abbas AK: Expression of bcl-X(L) restores cell survival, but not proliferation off effector differentiation, in CD28-deficient T lymphocytes. J Exp Med 2000, 191:2031-2038[Abstract/Free Full Text]
31. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 1997, 389:300-305[Medline]
32. Amundson SA, Myers TG, Fornace AJ, Jr: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998, 17:3287-3299[Medline]
33. Gu Z, Flemington C, Chittenden T, Zambetti GP: ei24, a p53 response gene involved in growth suppression and apoptosis. Mol Cell Biol 2000, 20:233-241[Abstract/Free Full Text]
34. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058[Abstract/Free Full Text]
35. Barkett M, Gilmore TD: Control of apoptosis by Rel/NF-B transcription factors. Oncogene 1999, 18:6910-6924[Medline]
36. Aggarwal BB: Apoptosis and nuclear factor-B: a tale of association and dissociation. Biochem Pharmacol 2000, 60:1033-1039[Medline]
37. Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH, Lai MZ: NF-B-dependent Fas ligand expression. Eur J Immunol 1999, 29:2948-2956[Medline]
38. Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Ju ST: Identification of two NF-B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 1998, 161:3469-3473[Abstract/Free Full Text]
39. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-B. Nature 1995, 376:167-170[Medline]
40. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M: The IKKß subunit of IB kinase (IKK) is essential for nuclear factor B activation and prevention of apoptosis. J Exp Med 1999, 189:1839-1845[Abstract/Free Full Text]
41. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV: Embryonic lethality, liver degeneration, and impaired NF-B activation in IKK-ß-deficient mice. Immunity 1999, 10:421-429[Medline]
42. Li Q, Estepa G, Memet S, Israel A, Verma IM: Complete lack of NF-B activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev 2000, 14:1729-1733[Abstract/Free Full Text]
43. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R: Genetic approaches in mice to understand Rel/NF-B and IB function: transgenics and knockouts. Oncogene 1999, 18:6888-6895[Medline]
44. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T, Feng L, Johnson RS, Karin M: Female mice heterozygous for IKK/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000, 5:969-979[Medline]
45. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, Rajewsky K, Pasparakis M: NEMO/IKK-deficient mice model incontinentia pigmenti. Mol Cell 2000, 5:981-992[Medline]
46. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N: Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol 2000, 156:997-1007[Abstract/Free Full Text]
47. Doi TS, Marino MW, Takahashi T, Yoshida T, Sakakura T, Old LJ, Obata Y: Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999, 96:2994-2999[Abstract/Free Full Text]
48. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM: Severe liver degeneration in mice lacking the IkB kinase 2 gene. Science 1999, 284:321-325[Abstract/Free Full Text]
49. Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995, 9:1527-1536[Abstract]
50. Joyce D, Bouzahzah B, Fu M, Albanese C, D’Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG: Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-B-dependent pathway. J Biol Chem 1999, 274:25245-25249[Abstract/Free Full Text]
51. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M: NF-B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999, 19:2690-2698[Abstract/Free Full Text]
52. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr: NF-B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19:5785-5799[Abstract/Free Full Text]
53. Chen F, Demers LM, Vallyathan V, Lu Y, Castranova V, Shi X: Involvement of 5'-flanking B-like sites within bcl-x gene in silica-induced Bcl-x expression. J Biol Chem 1999, 274:35591-35595[Abstract/Free Full Text]
54. Chen C, Edelstein LC, Gelinas C: The Rel/NF-B family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695[Abstract/Free Full Text]
55. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr: NF-B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683[Abstract/Free Full Text]
56. Ivanov VN, Lee RK, Podack ER, Malek TR: Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-B. Oncogene 1997, 14:2455-2464[Medline]
57. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-B and AP-1. Mol Cell 1998, 1:543-551[Medline]
58. Rivera-Walsh I, Cvijic ME, Xiao G, Sun SC: The NF-B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death. J Biol Chem 2000, 275:25222-25230[Abstract/Free Full Text]
59. Latinis KM, Norian LA, Eliason SL, Koretzky GA: Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem 1997, 272:31427-31434[Abstract/Free Full Text]
60. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM: The NF-B/Rel family of proteins mediates Ab-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 1998, 57:63-72[Medline]
61. Guo Q, Robinson N, Mattson MP: Secreted b-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-B and stabilization of calcium homeostasis. J Biol Chem 1998, 273:12341-12351[Abstract/Free Full Text]
62. Yu Z, Zhou D, Bruce-Keller AJ, Kindy MS, Mattson MP: Lack of the p50 subunit of nuclear factor-B increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 1999, 19:8856-8865[Abstract/Free Full Text]
63. Mattson MP, Camandola S: NF-B in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001, 107:247-254[Medline]
64. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T: NF-B subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999, 18:5177-5186[Medline]
65. Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES, Collins T: CREB-binding protein is a nuclear integrator of nuclear factor-B and p53 signaling. J Biol Chem 1999, 274:1879-1882[Abstract/Free Full Text]
66. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA, Tanaka N: Overexpression of the wild-type p53 gene inhibits NF-B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 2000, 19:726-736[Medline]
67. Ariumi Y, Kaida A, Lin JY, Hirota M, Masui O, Yamaoka S, Taya Y, Shimotohno K: HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000, 19:1491-1499[Medline]
68. Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN: Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-B pathway and is dependent on p53 phosphorylation. Mol Cell Biol 2000, 20:3377-3386[Abstract/Free Full Text]
69. Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, Doi TS, Takahashi T, Obata Y, Yoshioka K, Yamamoto K: p300/CBP-dependent and -independent transcriptional interference between NF-B RelA and p53. Biochem Biophys Res Commun 2000, 272:375-379[Medline]
70. Jung M, Kondratyev A, Lee SA, Dimtchev A, Dritschilo A: ATM gene product phosphorylates IB-. Cancer Res 1997, 57:24-27[Abstract/Free Full Text]
71. Ashburner BP, Shackelford RE, Baldwin AS, Jr, Paules RS: Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-kB (NF-kB) in human diploid fibroblasts. Cancer Res 1999, 59:5456-5460[Abstract/Free Full Text]
72. Liu L, Kwak YT, Bex F, Garcia-Martinez LF, Li XH, Meek K, Lane WS, Gaynor RB: DNA-dependent protein kinase phosphorylation of IB and IBß regulates NF-B DNA binding properties. Mol Cell Biol 1998, 18:4221-4234[Abstract/Free Full Text]
73. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-B in p53-mediated programmed cell death. Nature 2000, 404:892-897[Medline]
74. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ: Regulation of NF-B by cyclin-dependent kinases associated with the p300 coactivator. Science 1997, 275:523-527[Abstract/Free Full Text]
75. Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW: Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-B loop. Nat Cell Biol 1999, 1:227-233[Medline]
76. Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of IB inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem 1997, 272:29419-29422[Abstract/Free Full Text]
77. Reuther JY, Baldwin AS, Jr: Apoptosis promotes a caspase-induced amino-terminal truncation of IB that functions as a stable inhibitor of NF-B. J Biol Chem 1999, 274:20664-20670[Abstract/Free Full Text]
78. Jung M, Zhang Y, Dimtchev A, Dritschilo A: Impaired regulation of nuclear factor-B results in apoptosis induced by radiation. Radiat Res 1998, 149:596-601[Medline]
79. Silverman N, Zhou R, Stoven S, Pandey N, Hultmark D, Maniatis T: A drosophila IB kinase complex required for relish cleavage and antibacterial immunity. Genes Dev 2000, 14:2461-2471[Abstract/Free Full Text]
80. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L: Activation of the NF-B pathway by caspase 8 and its homologs. Oncogene 2000, 19:4451-4460[Medline]
81. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G: Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-B. J Biol Chem 2000, 276:4812-4818[Abstract/Free Full Text]
82. Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, Millar DG, Bouchard D, Wakeham A, Ohashi PS, Mak TW: Bcl10 is a positive regulator of antigen receptor-induced activation of NF-B and neural tube closure. Cell 2001, 104:33-42[Medline]
83. Poyet JL, Srinivasula SM, Alnemri ES: vCLAP, a caspase recruitment domain-containing protein of equine herpesvirus-2, persistently activates the IB kinases through oligomerization of IKK. J Biol Chem 2001, 276:3183-3187[Abstract/Free Full Text]
84. Nurse P: A long twentieth century of the cell cycle and beyond. Cell 2000, 100:71-78[Medline]
85. Shackelford RE, Kaufmann WK, Paules RS: Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999, 107(Suppl 1):S5-S24
86. Sheikh MS, Hollander MC, Fornance AJ, Jr: Role of Gadd45 in apoptosis. Biochem Pharmacol 2000, 59:43-45[Medline]
87. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000, 83:817-825[Medline]
88. Jimenez GS, Khan SH, Stommel JM, Wahl GM: p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999, 18:7656-7665[Medline]
89. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O’Connor PM, Piwnica-Worms H: The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000, 275:5600-5605[Abstract/Free Full Text]
90. Hutchins JR, Hughes M, Clarke PR: Substrate specificity determinants of the checkpoint protein kinase Chk1. FEBS Lett 2000, 466:91-95[Medline]
91. Baldwin AS, Jr, Azizkhan JC, Jensen DE, Beg AA, Coodly LR: Induction of NF-B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol Cell Biol 1991, 11:4943-4951[Abstract/Free Full Text]
92. Cressman DE, Greenbaum LE, Haber BA, Taub R: Rapid activation of post-hepatectomy factor/nuclear factor B in hepatocytes, a primary response in the regenerating liver. J Biol Chem 1994, 269:30429-30435[Abstract/Free Full Text]
93. Duckett CS, Perkins ND, Leung K, Agranoff AB, Nabel GJ: Cytokine induction of nuclear factor B in cycling and growth-arrested cells. Evidence for cell cycle-independent activation. J Biol Chem 1995, 270:18836-18840[Abstract/Free Full Text]
94. Yamada Y, Kirillova I, Peschon JJ, Fausto N: Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997, 94:1441-1446[Abstract/Free Full Text]
95. Biswas DK, Cruz AP, Gansberger E, Pardee AB: Epidermal growth factor-induced nuclear factor B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97:8542-8547[Abstract/Free Full Text]
96. Bash J, Zong WX, Gelinas C: c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol 1997, 17:6526-6536[Abstract]
97. Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J, Seo H: Inhibition of nuclear factor-B activation confers sensitivity to tumor necrosis factor-a by impairment of cell cycle progression in human glioma cells. Cancer Res 1999, 59:4446-4452[Abstract/Free Full Text]
98. Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W, Schmitz ML: Repression of NF-B impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene 1999, 18:3213-3225[Medline]
99. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258:424-429[Abstract/Free Full Text]
100. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163[Free Full Text]
101. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330[Medline]
102. Sheehy AM, Schlissel MS: Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. J Biol Chem 1999, 274:8708-8716[Abstract/Free Full Text]
103. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N, Akira S: Limb and skin abnormalities in mice lacking IKK. Science 1999, 284:313-316[Abstract/Free Full Text]
104. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M: Abnormal morphogenesis but intact IKK activation in mice lacking the IKK subunit of IB kinase. Science 1999, 284:316-320[Abstract/Free Full Text]
105. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X: Opposite effect of NF-B and c-Jun-N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001, 276:11414-11419[Abstract/Free Full Text]
106. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE: Aberrant nuclear factor-B/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100:2952-2960[Medline]
107. Mukhopadhyay T, Roth JA, Maxwell SA: Altered expression of the p50 subunit of the NF-B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995, 11:999-1003[Medline]
108. Gilmore TD, Koedood M, Piffat KA, White DW: Rel/NF-B/IB proteins and cancer. Oncogene 1996, 13:1367-1378[Medline]
109. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dorken B: High-level nuclear NF-B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347[Abstract/Free Full Text]
110. Devalaraja MN, Wang DZ, Ballard DW, Richmond A: Elevated constitutive IB kinase activity and IB phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO- transcription. Cancer Res 1999, 59:1372-1377[Abstract/Free Full Text]
111. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V: Regulation of NF-B activity by IB-related proteins in adenocarcinoma cells. Oncogene 1999, 18:2567-2577[Medline]
112. Sumitomo M, Tachibana M, Ozu C, Asakura H, Murai M, Hayakawa M, Nakamura H, Takayanagi A, Shimizu N: Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IB overexpression. Hum Gene Ther 1999, 10:37-47[Medline]
113. Miwa M, Kushida S, Maeda N, Fang J, Kawamura T, Kameyama T, Uchida K: Pathogenesis and prevention of HTLV-1-associated diseases. Leukemia 1997, 11(Suppl 3):S65-S66
114. Berger C, Brousset P, McQuain C, Knecht H: Deletion variants within the NF-B activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leuk Lymphoma 1997, 26:239-250[Medline]
115. Nasti G, Vaccher E, Errante D, Tirelli U: Malignant tumors and AIDS. Biomed Pharmacother 1997, 51:243-251[Medline]
116. Carrasco D, Rizzo CA, Dorfman K, Bravo R: The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 1996, 15:3640-3650[Medline]
117. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R: B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-B p50. Cell 1991, 67:1075-1087[Medline]
118. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo AT, Neri A: Structural alterations of the NF-B transcription factor lyt-10 in lymphoid malignancies. Oncogene 1993, 8:2839-2845[Medline]
119. Liptay S, Seriu T, Bartram CR, Schmid RM: Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL). Leukemia 1997, 11:1364-1366[Medline]
120. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RS: REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996, 87:25-29[Abstract/Free Full Text]
121. Michaux L, Dierlamm J, Wlodarska I, Bours V, Van den Berghe H, Hagemeijer A: t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet 1997, 94:36-43[Medline]
122. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT: Mutations in the IB gene in Hodgkin’s disease suggest a tumour suppressor role for IB. Oncogene 1999, 18:3063-3070[Medline]
123. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70[Medline]
124. Mettouchi A, Cabon F, Montreau N, Dejong V, Vernier P, Gherzi R, Mercier G, Binetruy B: The c-Jun-induced transformation process involves complex regulation of tenascin-C expression. Mol Cell Biol 1997, 17:3202-3209[Abstract]
125. Schwartz SA, Hernandez A, Mark Evers B: The role of NF-B/IB proteins in cancer: implications for novel treatment strategies. Surg Oncol 1999, 8:143-153[Medline]
126. Mayo MW, Baldwin AS: The transcription factor NF-B: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000, 1470:M55-M62[Medline]
127. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-B. J Clin Invest 2001, 107:241-246[Medline]
128. Wang CY, Cusack JC, Liu R, Baldwin AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B. Nat Med 1999, 5:412-417[Medline]
129. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, Schafer H: Inhibition of the NF-B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001, 20:859-868[Medline]
130. Jones DR, Broad RM, Madrid LV, Baldwin AS, Mayo MW: Inhibition of NF-B sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 2000, 70:930-937[Abstract/Free Full Text]
131. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, Van Waes C: Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-B. Head Neck 2000, 22:748-759[Medline]
132. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G, Del Vecchio L, Turco MC, Venuta S: Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-B/Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000, 7:1234-1237[Medline]
133. Cusack JC, Liu R, Baldwin AS: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-B activation. Cancer Res 2000, 60:2323-2330[Abstract/Free Full Text]
134. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP: Nuclear factor-B, cancer, and apoptosis. Biochem Pharmacol 2000, 60:1085-1089[Medline]

This article has been cited by other articles:

				C.-J. Weng, C.-F. Chau, Y.-S. Hsieh, S.-F. Yang, and G.-C. Yen Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-{kappa}B and AP-1 Carcinogenesis, January 1, 2008; 29(1): 147 - 156. [Abstract] [Full Text] [PDF]

				T. Aoki, H. Kataoka, M. Shimamura, H. Nakagami, K. Wakayama, T. Moriwaki, R. Ishibashi, K. Nozaki, R. Morishita, and N. Hashimoto NF-{kappa}B Is a Key Mediator of Cerebral Aneurysm Formation Circulation, December 11, 2007; 116(24): 2830 - 2840. [Abstract] [Full Text] [PDF]

				O. Pekar, N. Molotski, S. Savion, A. Fein, V. Toder, and A. Torchinsky p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-{kappa}B DNA binding Reproduction, August 1, 2007; 134(2): 379 - 388. [Abstract] [Full Text] [PDF]

				C. Morais, B. Pat, G. Gobe, D. W. Johnson, and H. Healy Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3377 - 3388. [Abstract] [Full Text] [PDF]

				F. Chen, Y. Lu, V. Castranova, Z. Li, and M. Karin Loss of Ikkbeta Promotes Migration and Proliferation of Mouse Embryo Fibroblast Cells J. Biol. Chem., December 1, 2006; 281(48): 37142 - 37149. [Abstract] [Full Text] [PDF]

				T. Chen, M. E. Rose, H. Hwang, R. G. Nines, and G. D. Stoner Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS Carcinogenesis, November 1, 2006; 27(11): 2301 - 2307. [Abstract] [Full Text] [PDF]

				S.-K. Jo, G. J. Ko, C. S. Boo, W. Y. Cho, and H. K. Kim Heat Preconditioning Attenuates Renal Injury in Ischemic ARF in Rats: Role of Heat-Shock Protein 70 on NF-{kappa}B-Mediated Inflammation and on Tubular Cell Injury J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3082 - 3092. [Abstract] [Full Text] [PDF]

				I Strickland and S Ghosh Use of cell permeable NBD peptides for suppression of inflammation Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii75 - iii82. [Abstract] [Full Text] [PDF]

				S. A. Madsen-Bouterse, G. J. M. Rosa, and J. L. Burton Glucocorticoid Modulation of Bcl-2 Family Members A1 and Bak during Delayed Spontaneous Apoptosis of Bovine Blood Neutrophils Endocrinology, August 1, 2006; 147(8): 3826 - 3834. [Abstract] [Full Text] [PDF]

				E. Rached, E. Pfeiffer, W. Dekant, and A. Mally Ochratoxin A: Apoptosis and Aberrant Exit from Mitosis due to Perturbation of Microtubule Dynamics? Toxicol. Sci., July 1, 2006; 92(1): 78 - 86. [Abstract] [Full Text] [PDF]

				M. C. Ralstin, E. A. Gage, M. T. Yip-Schneider, P. J. Klein, E. A. Wiebke, and C. M. Schmidt Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells through Effects on Apoptosis and G0-G1 Cell Cycle Arrest Mol. Cancer Res., June 1, 2006; 4(6): 387 - 399. [Abstract] [Full Text] [PDF]

				Y. Kang, S.-K. Kang, Y.-C. Lee, H.-J. Choi, Y.-S. Lee, S.-Y. Cho, Y.-S. Kim, J.-H. Ko, and C.-H. Kim Transcriptional regulation of the human GD3 synthase gene expression in Fas-induced Jurkat T cells: a critical role of transcription factor NF-{kappa}B in regulated expression Glycobiology, May 1, 2006; 16(5): 375 - 389. [Abstract] [Full Text] [PDF]

				L. Emdad, D. Sarkar, Z.-z. Su, A. Randolph, H. Boukerche, K. Valerie, and P. B. Fisher Activation of the Nuclear Factor {kappa}B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis Cancer Res., February 1, 2006; 66(3): 1509 - 1516. [Abstract] [Full Text] [PDF]

				Y.-J. Surh, J. K. Kundu, H.-K. Na, and J.-S. Lee Redox-Sensitive Transcription Factors as Prime Targets for Chemoprevention with Anti-Inflammatory and Antioxidative Phytochemicals J. Nutr., December 1, 2005; 135(12): 2993S - 3001S. [Abstract] [Full Text] [PDF]

				N. Takahashi, S. Kobayashi, S. Kajino, K. Imai, K. Tomoda, S. Shimizu, and T. Okamoto Inhibition of the 53BP2S-mediated apoptosis by nuclear factor {kappa}B and Bcl-2 family proteins Genes Cells, August 1, 2005; 10(8): 803 - 811. [Abstract] [Full Text] [PDF]

				X. P. Yang, K. Irani, S. Mattagajasingh, A. DiPaula, F. Khanday, M. Ozaki, K. Fox-Talbot, W. M. Baldwin III, and L. C. Becker Signal Transducer and Activator of Transcription 3{alpha} and Specificity Protein 1 Interact to Upregulate Intercellular Adhesion Molecule-1 in Ischemic-Reperfused Myocardium and Vascular Endothelium Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1395 - 1400. [Abstract] [Full Text] [PDF]

				S. Saika, T. Miyamoto, O. Yamanaka, T. Kato, Y. Ohnishi, K. C. Flanders, K. Ikeda, Y. Nakajima, W. W.-Y. Kao, M. Sato, et al. Therapeutic Effect of Topical Administration of SN50, an Inhibitor of Nuclear Factor-{kappa}B, in Treatment of Corneal Alkali Burns in Mice Am. J. Pathol., May 1, 2005; 166(5): 1393 - 1403. [Abstract] [Full Text] [PDF]

				M. T. Yip-Schneider, H. Nakshatri, C. J. Sweeney, M. S. Marshall, E. A. Wiebke, and C. M. Schmidt Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-{kappa}B pathway in pancreatic carcinoma cells Mol. Cancer Ther., April 1, 2005; 4(4): 587 - 594. [Abstract] [Full Text] [PDF]

				H. Guan, S. Hou, and R. P. Ricciardi DNA Binding of Repressor Nuclear Factor-{kappa}B p50/p50 Depends on Phosphorylation of Ser337 by the Protein Kinase A Catalytic Subunit J. Biol. Chem., March 18, 2005; 280(11): 9957 - 9962. [Abstract] [Full Text] [PDF]

				L.-G. Bladh, J. Liden, A. Pazirandeh, I. Rafter, K. Dahlman-Wright, S. Nilsson, and S. Okret Identification of Target Genes Involved in the Antiproliferative Effect of Glucocorticoids Reveals a Role for Nuclear Factor-{kappa}B Repression Mol. Endocrinol., March 1, 2005; 19(3): 632 - 643. [Abstract] [Full Text] [PDF]

				L. Tacchini, C. De Ponti, E. Matteucci, R. Follis, and M.A. Desiderio Hepatocyte growth factor-activated NF-{kappa}B regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines Carcinogenesis, November 1, 2004; 25(11): 2089 - 2100. [Abstract] [Full Text] [PDF]

				J.-C. Albrecht, B. Biesinger, I. Muller-Fleckenstein, D. Lengenfelder, M. Schmidt, B. Fleckenstein, and A. Ensser Herpesvirus Ateles Tio Can Replace Herpesvirus Saimiri StpC and Tip Oncoproteins in Growth Transformation of Monkey and Human T Cells J. Virol., September 15, 2004; 78(18): 9814 - 9819. [Abstract] [Full Text] [PDF]

				M.-S. Chang, W.-S. Lee, B.-C. Chen, J.-R. Sheu, and C.-H. Lin YC-1-Induced Cyclooxygenase-2 Expression Is Mediated by cGMP-Dependent Activations of Ras, Phosphoinositide-3-OH-kinase, Akt, and Nuclear Factor-{kappa}B in Human Pulmonary Epithelial Cells Mol. Pharmacol., September 1, 2004; 66(3): 561 - 571. [Abstract] [Full Text] [PDF]

				C. Albrecht, R. P. F. Schins, D. Hohr, A. Becker, T. Shi, A. M. Knaapen, and P. J. A. Borm Inflammatory Time Course after Quartz Instillation: Role of Tumor Necrosis Factor-{alpha} and Particle Surface Am. J. Respir. Cell Mol. Biol., September 1, 2004; 31(3): 292 - 301. [Abstract] [Full Text] [PDF]

				S.-J. Jeong, M. Radonovich, J. N. Brady, and C. A. Pise-Masison HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity Blood, September 1, 2004; 104(5): 1490 - 1497. [Abstract] [Full Text] [PDF]

				S. Mitra-Kaushik, J. C. Harding, J. L. Hess, and L. Ratner Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants Blood, August 1, 2004; 104(3): 802 - 809. [Abstract] [Full Text] [PDF]

				M. Flores-Diaz, J.-C. Higuita, I. Florin, T. Okada, P. Pollesello, T. Bergman, M. Thelestam, K. Mori, and A. Alape-Giron A Cellular UDP-glucose Deficiency Causes Overexpression of Glucose/Oxygen-regulated Proteins Independent of the Endoplasmic Reticulum Stress Elements J. Biol. Chem., May 21, 2004; 279(21): 21724 - 21731. [Abstract] [Full Text] [PDF]

				S. Shukla and S. Gupta Suppression of Constitutive and Tumor Necrosis Factor {alpha}-Induced Nuclear Factor (NF)-{kappa}B Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF-{kappa}B-Responsive Genes Clin. Cancer Res., May 1, 2004; 10(9): 3169 - 3178. [Abstract] [Full Text] [PDF]

				N. Yamanaka, T. Morisaki, H. Nakashima, A. Tasaki, M. Kubo, H. Kuga, C. Nakahara, K. Nakamura, H. Noshiro, T. Yao, et al. Interleukin 1{beta} Enhances Invasive Ability of Gastric Carcinoma through Nuclear Factor-{kappa}B Activation Clin. Cancer Res., March 1, 2004; 10(5): 1853 - 1859. [Abstract] [Full Text] [PDF]

				J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, G L Scheffer, R J Scheper, Y G Assaraf, and G Jansen Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs Ann Rheum Dis, February 1, 2004; 63(2): 131 - 137. [Abstract] [Full Text] [PDF]

				J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, C G Schalkwijk, G L Scheffer, R J Scheper, and G Jansen Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF{alpha} Ann Rheum Dis, February 1, 2004; 63(2): 138 - 143. [Abstract] [Full Text] [PDF]

				P. Mistry, K. Deacon, S. Mistry, J. Blank, and R. Patel NF-{kappa}B Promotes Survival during Mitotic Cell Cycle Arrest J. Biol. Chem., January 9, 2004; 279(2): 1482 - 1490. [Abstract] [Full Text] [PDF]

				M. A. C. Pratt, T. E. Bishop, D. White, G. Yasvinski, M. Menard, M. Y. Niu, and R. Clarke Estrogen Withdrawal-Induced NF-{kappa}B Activity and Bcl-3 Expression in Breast Cancer Cells: Roles in Growth and Hormone Independence Mol. Cell. Biol., October 1, 2003; 23(19): 6887 - 6900. [Abstract] [Full Text] [PDF]

				Y. Yu, H. Zeng, S. Lyons, A. Carlson, D. Merlin, A. S. Neish, and A. T. Gewirtz TLR5-mediated activation of p38 MAPK regulates epithelial IL-8 expression via posttranscriptional mechanism Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G282 - G290. [Abstract] [Full Text] [PDF]

				S. Dihlmann, S. Klein, and M. v. K. Doeberitz Reduction of {beta}-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated {beta}-Catenin Mol. Cancer Ther., June 1, 2003; 2(6): 509 - 516. [Abstract] [Full Text] [PDF]

				S. Chen, Z. A. Khan, M. Cukiernik, and S. Chakrabarti Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1089 - E1097. [Abstract] [Full Text] [PDF]

				F. Galbiati, L. Polastri, B. Thorens, P. Dupraz, P. Fiorina, U. Cavallaro, G. Christofori, and A. M. Davalli Molecular Pathways Involved in the Antineoplastic Effects of Calcitriol on Insulinoma Cells Endocrinology, May 1, 2003; 144(5): 1832 - 1841. [Abstract] [Full Text] [PDF]

				S. Han and N. Sidell RU486-Induced Growth Inhibition of Human Endometrial Cells Involves the Nuclear Factor-{kappa}B Signaling Pathway J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 713 - 719. [Abstract] [Full Text] [PDF]

				S. Chen, S. Mukherjee, C. Chakraborty, and S. Chakrabarti High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1 Am J Physiol Cell Physiol, February 1, 2003; 284(2): C263 - C272. [Abstract] [Full Text] [PDF]

				S. T. Nawrocki, C. J. Bruns, M. T. Harbison, R. J. Bold, B. S. Gotsch, J. L. Abbruzzese, P. Elliott, J. Adams, and D. J. McConkey Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts Mol. Cancer Ther., December 1, 2002; 1(14): 1243 - 1253. [Abstract] [Full Text] [PDF]

				H Eguchi and S F Moss Helicobacter pylori Mol. Pathol., October 1, 2002; 55(5): 284 - 285. [Full Text] [PDF]

				G. G. Mackenzie, M. P. Zago, C. L. Keen, and P. I. Oteiza Low Intracellular Zinc Impairs the Translocation of Activated NF-kappa B to the Nuclei in Human Neuroblastoma IMR-32 Cells J. Biol. Chem., September 6, 2002; 277(37): 34610 - 34617. [Abstract] [Full Text] [PDF]

				M. Hinz, P. Lemke, I. Anagnostopoulos, C. Hacker, D. Krappmann, S. Mathas, B. Dorken, M. Zenke, H. Stein, and C. Scheidereit Nuclear Factor {kappa}B-dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity J. Exp. Med., September 2, 2002; 196(5): 605 - 617. [Abstract] [Full Text] [PDF]

				S. T. Sonis THE BIOLOGIC ROLE FOR NUCLEAR FACTOR-KAPPAB IN DISEASE AND ITS POTENTIAL INVOLVEMENT IN MUCOSAL INJURY ASSOCIATED WITH ANTI-NEOPLASTIC THERAPY Critical Reviews in Oral Biology & Medicine, September 1, 2002; 13(5): 380 - 389. [Abstract] [Full Text] [PDF]

				C. M. Tato and C. A. Hunter Host-Pathogen Interactions: Subversion and Utilization of the NF-{kappa}B Pathway during Infection Infect. Immun., July 1, 2002; 70(7): 3311 - 3317. [Full Text] [PDF]

				A. Tiran, H.-J. Gruber, W. F. Graier, A. H. Wagner, E. B.M. van Leeuwen, and B. Tiran Aspirin Inhibits Chlamydia pneumoniae-Induced Nuclear Factor-{kappa}B Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1075 - 1080. [Abstract] [Full Text] [PDF]

				Y. Wang, E. Asselin, and B. K. Tsang Involvement of Transforming Growth Factor {alpha} in the Regulation of Rat Ovarian X-Linked Inhibitor of Apoptosis Protein Expression and Follicular Growth by Follicle-Stimulating Hormone Biol Reprod, June 1, 2002; 66(6): 1672 - 1680. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, V. G. Gorgoulis, and A. G. Papavassiliou Transcription Factors and Neoplasia: Vistas in Novel Drug Design Clin. Cancer Res., May 1, 2002; 8(5): 949 - 961. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, F. Articles by Shi, X. Search for Related Content PubMed PubMed Citation Articles by Chen, F. Articles by Shi, X.